EUCTR2008-000193-21-GR
Active, not recruiting
Not Applicable
A multicenter, randomized, double-blind, double-dummy, placebo-controlled, 3-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol combination administered with Elpenhaler®db (Rolenium®) versus the innovative one (Seretide Diskus®) in patients with asthma.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Elpen Pharmaceutical Co. Inc.
- Enrollment
- 42
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Study subjects are eligible for participation if they meet all of the following criteria:
- •1\.Age 18\-65 male or female.
- •2\.Clinical diagnosis of asthma of ? 6 months prior to screening visit.
- •3\.FEV1 \= 50% and \= 80% predicted.
- •4\.Airways obstruction reversibility of at least 12% FEV1 (and an absolute increase of at least 0\.2 lt) after 400µg of inhaled salbutamol.
- •5\.Stable asthma for at least 4 weeks prior to screening visit.
- •6\.Inhaled steroids (ICS) at a stable dose within the previous 30 days of screening visit and short acting ß2\-agonists on an as needed basis.
- •7\.PIF 30 \- 90 lt/min.
- •8\.Patients willing to collaborate at the study visits.
- •9\.Signed and dated written informed consent.
Exclusion Criteria
- •Patients who meet any of the following exclusion criteria are not eligible for enrolment into the study:
- •1\.History of other pulmonary disease, such as COPD, tuberculosis, cystic fibrosis, bronchiectasis.
- •2\.Asthma exacerbation or respiratory infection within the previous 4 weeks.
- •3\.Hospitalization for acute asthmatic symptoms requiring parenteral steroids or oral steroid dose increase within the previous 30 days of screening visit.
- •4\.Heavy smokers (\>10 cigarettes per day) or any smoking history \=10 pack years.
- •5\.Change of asthma medication within the previous 4 weeks of screening visit.
- •6\.Seasonal asthma alone or patients who are likely to have a major exacerbation of their asthma due to seasonal effects during the study period.
- •7\.Unusual responsiveness to sympathomimetic amines.
- •8\.History of ischemic heart disease, severe heart failure, myocardial infarction, tachyarrhythmias, cardiac arrhythmias, third degree atrioventricular block, decompensated heart failure, idiopathic subvalvular aortic stenosis, hypertrophic obstructive cardiomyopathy, severe hypertension, prolongation of the QTc\>0\.44s, aneurysm, convulsive disorders, thyrotoxicosis and pheochromocytoma.
- •9\.Other severe acute or chronic medical or psychiatric condition, which in the opinion of the investigator may increase the risk of patient’s participation or may confound the study results.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Efficacy and safety of finerenone in subjects with chronic heart failure at high risk of recurrent heart failure decompensatioSubjects with chronic heart failure and reduced ejection fraction after recent heart failure decompensation and additional risk factors, either type 2 diabetes mellitus or chronic kidney disease or bothMedDRA version: 18.0 Level: LLT Classification code 10076410 Term: Chronic kidney disease stage 3 System Organ Class: 100000004857MedDRA version: 18.0 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus System Organ Class: 100000004861MedDRA version: 18.0 Level: LLT Classification code 10066498 Term: Cardiac failure chronic aggravated System Organ Class: 100000004849MedDRA version: 18.0 Level: LLT Classification code 10076408 Term: Chronic kidney disease stage 1 System Organ Class: 100000004857MedDRA version: 18.0 Level: LLT Classification code 10076409 Term: Chronic kidney disease stage 2 System Organ Class: 100000004857Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2015-002168-17-IEBayer HealthCare AG5,890
Active, not recruiting
Phase 1
Efficacy and safety of finerenone in subjects with chronic heart failure at high risk of recurrent heart failure decompensatioEUCTR2015-002168-17-CZBayer HealthCare AG5,890
Active, not recruiting
Phase 1
Efficacy and safety of finerenone in subjects with chronic heart failure at high risk of recurrent heart failure decompensatioSubjects with chronic heart failure and reduced ejection fraction after recent heart failure decompensation and additional risk factors, either type 2 diabetes mellitus or chronic kidney disease or bothMedDRA version: 18.1 Level: LLT Classification code 10076410 Term: Chronic kidney disease stage 3 System Organ Class: 100000004857MedDRA version: 18.1 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus System Organ Class: 100000004861MedDRA version: 18.1 Level: LLT Classification code 10066498 Term: Cardiac failure chronic aggravated System Organ Class: 100000004849MedDRA version: 18.1 Level: LLT Classification code 10076408 Term: Chronic kidney disease stage 1 System Organ Class: 100000004857MedDRA version: 18.1 Level: LLT Classification code 10076409 Term: Chronic kidney disease stage 2 System Organ Class: 100000004857Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2015-002168-17-LTBayer HealthCare AG5,890
Active, not recruiting
Not Applicable
A multicenter, randomized, double-blind, double-dummy, placebo-controlled, 3-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol combination administered with Elpenhaler®db (Rolenium®) versus the innovative one (Seretide Diskus®) in patients with asthma.Chronic Persistent AsthmaMedDRA version: 9.1Level: LLTClassification code 10003561Term: Asthma, unspecifiedEUCTR2008-000193-21-HUElpen Pharmaceutical Co. Inc.42
Active, not recruiting
Phase 1
Efficacy and safety of finerenone in subjects with chronic heart failure at high risk of recurrent heart failure decompensatioSubjects with chronic heart failure and reduced ejection fraction after recent heart failure decompensation and additional risk factors, either type 2 diabetes mellitus or chronic kidney disease or bothMedDRA version: 18.1Level: LLTClassification code 10076410Term: Chronic kidney disease stage 3System Organ Class: 100000004857MedDRA version: 18.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861MedDRA version: 18.1Level: LLTClassification code 10066498Term: Cardiac failure chronic aggravatedSystem Organ Class: 100000004849MedDRA version: 18.1Level: LLTClassification code 10076408Term: Chronic kidney disease stage 1System Organ Class: 100000004857MedDRA version: 18.1Level: LLTClassification code 10076409Term: Chronic kidney disease stage 2System Organ Class: 100000004857Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2015-002168-17-BEBayer HealthCare AG5,890